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1. Introduction 
Noninvasive positive pressure ventilation (NPPV) refers to the administration of ventilatory 
support without using an invasive artificial airway (endotracheal tube or tracheostomy 
tube). The use of NPPV has markedly increased over the past two decades. Rudimentary 
devices that provided continuous positive airway pressure were described in the 1930s, but 
the negative-pressure ventilators were the predominant method of ventilatory support until 
the polio epidemics overwhelmed their capacity in the 1950s. In the 1980s, increasing 
experience with positive-pressure ventilation delivered through a mask in patients with 
obstructive sleep apnea led to this type of ventilatory support, initially in patients with 
neuromuscular respiratory failure. Success led to its adoption in other conditions, and 
NPPV became especially promising in the treatment of patients with exacerbations of 
chronic obstructive pulmonary disease (COPD).  
NPPV is defined as ventilatory support delivered by a non-invasive interface such as mask 
or similar device, acting as an alternative to intubation or tracheostomy. Consequently, by 
avoiding tracheal intubation, NPPV presents several potential advantages, such as reduction 
in pulmonary infections, barotrauma and need for sedation (British Thoracic Society 
Standards of Care Committee  2002). As a result, NPPV should be considered a standard of 
care to treat COPD exacerbation in selected patients, since it markedly reduces the need for 
intubation and improves outcome by lowering complication and mortality rates, and 
shortening hospital stay (Brochard et al. 1995; Kramer et al. 1995; Celikel et al. 1998; Martin 
et al. 2000; Conti et al. 2002; Squadrone et al. 2004; Lightowler et al. 2003; Nava, Navalesi, & 
Conti 2006). Weaker evidence indicates that NPPV could allow earlier extubation, avoid re-
intubation in patients who fail extubation, and assist do-not-intubate patients, and thus 
could be beneficial for COPD patients who are suffering respiratory failure precipitated by 
superimposed pneumonia or postoperative complications, and COPD patients with severe 
stable disease who have substantial daytime hypercapnia and superimposed nocturnal 
hypoventilation.  
This chapter will examine the evidence pertaining to the use of NPPV for various 
applications in COPD and make recommendation on patient, ventilation mode and interface 
selection as well as technical aspects of NPPV application in COPD. The literature review 
www.intechopen.com
 
Chronic Obstructive Pulmonary Disease – Current Concepts and Practice 
 
334 
and consensus processes used to reach the recommendations presented here are the 
American College of Chest Physicians [ACCP] consensus report on clinical indications for 
NPPV in CRF due to restrictive lung disease, COPD and nocturnal hypoventilation 
published in 1999, the British Thoracic Society guidelines published in 2002, the Indian 
Society of Critical Care Medicine guidelines published in 2006, the guidelines from 12 
German Medical Societies published in 2008 and the most recent guideline published in 
2011 from Canadian Critical Care Trials Group/Canadian Critical Care Society Noninvasive 
Ventilation Guidelines Group.  
2. Physiologic mechanism of NPPV effect in patients with COPD 
Severe COPD places the respiratory muscles at a mechanical disadvantage (Rochester, 
Braun, & Arora 1979). During COPD exacerbation, this situation becomes catastrophic. 
Exacerbations of COPD increase the respiratory load in these patients, exceeding their 
ability to adequately ventilate through a variety of mechanisms, including increasing 
hyperinflation with decreased diaphragmatic excursion and strength, increasing intrinsic 
positive end-expiratory pressure (PEEP), changes in respiratory patterns and increased 
respiratory frequency leading to ineffective or inadequate tidal volume generation. NPPV 
effectively unloads the respiratory muscles by increasing tidal volume, decreasing the 
respiratory rate, and decreasing the diaphragmatic work of breathing, which translates into 
an improvement in oxygenation, a reduction in hypercapnia, and an improvement in 
dyspnea. NPPV  treatment counterbalances auto-PEEP, assists inspiration, reduces 
transdiaphragmatic pressure, lowers respiratory rate, rests the accessory muscles, increases 
functional residual capacity, decreases respiratory load and work of breathing and leads to 
favorable changes in the ventilation/perfusion ratio as well as the respiratory center and the 
sensivity of chemoreceptors (Mansfield & Naughton 1999; de Miguel et al. 2002). Expiration 
positive airway pressure (EPAP) counterbalances intrinsic PEEP. Inspiration positive airway 
pressure (IPAP) is capable of increasing tidal volume and subsequently decreasing the 
elevated levels of PC02.  
3. Indications of NPPV in patients with COPD 
3.1 Acute respiratory failure/Exacerbation of COPD 
Based upon the overwhelming evidence that NPPV reduces the need for intubation, reduces 
mortality and complications rates, and shortens the length of stay in both the intensive care 
unit (ICU) and hospital (Kramer et al. 1995; Brochard et al. 1995; Celikel et al. 1998; Martin et 
al. 2000; Carlucci et al. 2001; Mehta & Hill 2001) , NPPV should be considered as a standard 
of care in acute respiratory failure (ARF) due to COPD exacerbations (Keenan et al. 2011). 
Brochard et al. were the first to show that pressure-support ventilation administered via face 
mask significantly reduced the need for intubation, duration of mechanical ventilation, and 
ICU stay in patients with COPD exacerbations (Brochard et al. 1990). The patients with 
relatively mild COPD exacerbations are not likely to benefit from NPPV, which suggests 
that NPPV should be applied to selected patients who have moderate-to-severe COPD 
exacerbations. Though, patients with milder exacerbations appear to demonstrate a more 
rapid improvement in their level of dyspnea with NPPV treatment, the addition of NPPV to 
standard therapy for patients with milder exacerbations of COPD is not well tolerated 
(Keenan, Powers, & McCormack 2005). NPPV should be the first option for ventilatory 
www.intechopen.com
 
Noninvasive Positive-Pressure Ventilation Therapy in Patients with COPD 
 
335 
support in patients with either a severe exacerbation of COPD or cardiogenic pulmonary 
edema(Keenan et al. 2011). Furthermore, consensus groups of experts advocate the routine 
use of NPPV for selected patients with COPD exacerbations (British Thoracic Society 
Standards of Care Committee  2002). High quality studies have shown that NPPV is an 
effective treatment for moderate to severe COPD exacerbation (Kramer et al. 1995; Celikel et 
al. 1998; Martin et al. 2000). In patients with mild to moderate ARF, characterized by pH 
levels between 7.25 and 7.35, the rate of NPPV failure was ranging from 15% to 20% (Elliott 
2002; Lightowler et al. 2003). In more severely ill patients (pH<7.25), the rate of NPPV 
failure was inversely related to the severity of respiratory acidosis, rising up to 52%-62% 
(Conti et al. 2002; Squadrone et al. 2004). In patients with ‘’mild’’ exacerbations, not 
complicated by respiratory acidosis, the use of NPPV was investigated in few studies, 
including patients in large majority with pH>7.35, which failed to demonstrate a better 
effectiveness of NPPV than standard medical therapy in preventing the occurrence of ARF 
(Bardi et al. 2000; Keenan, Powers, & McCormack 2005). Guidelines recommend the use of 
NPPV in addition to usual care in patients who have a severe exacerbation of COPD 
(pH<7.35 and relative hypercarbia) (grade 1A recommendation) (Keenan et al. 2011). Based 
on that evidence, the authors of the meta-analyses and the participants in the consensus 
groups recommended that NPPV should be used early in the course of a COPD 
exacerbation, in addition to the standard medical care (Lightowler et al. 2003; Keenan et al. 
2003; British Thoracic Society Standards of Care Committee  2002) . NPPV is not appropriate 
for all COPD patients with ARF and the selection of candidates is important. Most of the 
indications and contraindications for NPPV in ARF are listed in Table 1 (Brochard et al. 
1995). There are no absolute contraindications to NPPV although a number have been 
suggested (Ambrosino et al. 1995; Soo Hoo, Santiago, & Williams 1994). In part, these 
contraindications have been determined by the fact that they were exclusion criteria for the 
controlled trials. It is therefore accurate to state that NPPV is not proven in these 
circumstances rather than stating that it is contraindicated. 
3.2 Severe community-acquired pneumonia in patients with COPD 
The presence of pneumonia has been associated with poor outcome in patients treated with 
NPPV (Ambrosino et al. 1995). However COPD exacerbation is still an appropriate 
indication for NPPV even when complicated by community-acquired pneumonia 
(Confalonieri et al. 1999). In one randomized trial with patients suffering severe community- 
acquired pneumonia, NPPV reduced the need for intubation, and reduced mortality among 
the COPD subgroup of patients 2 months after hospital discharge (Confalonieri et al. 1999). 
But it is not clear whether NPPV should be used for severe community-acquired pneumonia 
in non-COPD patients.  
3.3 Adjunct to early liberation 
Patients with COPD can be considered for a trial of early extubation to NPPV in centres with 
extensive experience in the use of  NPPV (Keenan et al. 2011). Guidelines suggest that NPPV 
be used to facilitate early liberation from mechanical ventilation in patients who have COPD, 
but only in centres that have expertise in this therapy (Grade 2B recommendation) (Keenan 
et al. 2011). Recent randomized controlled trials (RCTs) suggested benefit from  
NPPV after extubation in patients who had high risk of deterioration (Ferrer et al. 2006;  
Ferrer et al. 2009; Nava et al. 2005; Luo, Cheng, & Zhou 2001). The results of the RCTs of  
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 Increased dyspnea-moderate to severe 
 Tachypnea (>25 breaths per minute) 
 Signs of increased work of breathing, accessory  muscle use, pursed lips breathing 
and abdominal paradox 
 Acute or chronic ventilatory failure (best indication), PaC02 >45 mmHg, pH <7.35 
 Hypoxaemia (use caution), Pa02/Fi02 ratio < 200 
Contraindications 
Absolute 
 Cardiac or respiratory arrest 
 Severe encephalopathy 
 Unable to fit mask 
Relative 
 Severe haemodynamic instability with or without cardiac ischemia or arrhythmia 
 Severe gastrointestinal bleeding 
 Agitated, uncooperative state 
 Upper airway obstruction 
 Inability to protect the airway and/or high risk of aspiration 
 Inability to clear secretions 
 Multiple organ failure 
 Recent facial, upper airway or upper gastrointestinal surgery 
[NPPV= non-invasive positive pressure ventilation; PaC02: arterial partial pressure of carbon dioxide; 
Pa02: arterial partial pressure of oxygen; Fi02: fraction of inspired oxygen] 
Table 1. Indications and contraindications for NPPV in ARF 
early extubation in COPD patients with NPPV are controversial, some showing significant 
benefit and the other showing no important benefit, but no attributable harm in either 
(Girault et al. 1999; Ferrer et al. 2003). Intubated COPD patients are appropriate candidates 
for early extubation by NPPV, but clinicians are advised to be cautious when selecting 
patients. The inability to sustain 5–10 min of unassisted breathing, a prior difficult 
intubation, multiple co-morbidities, copious secretions, a weakened cough, or the need for 
high levels of pressure support prior to extubation (>20 cm H2O) should exclude patients 
from consideration for early extubation (Hill 2004).   
3.4 After planned extubation 
Extubation failure occurs after  5-20% of planned (Epstein, Ciubotaru, and Wong 1997) and 
40-50% of unplanned extubation (Chevron et al. 1998) NPPV may prevent the need for 
reintubation if applied immediately after planned extubation. NPPV is recommended to be 
used after planned extubation in patients who are considered to be at high risk of recurrent 
respiratory failure, but only in centres that have expertise in this type of therapy (Grade 2B 
recommendation) (Keenan et al. 2011). We should be careful to avoid delays in intubation in 
the face of deterioration and to select the patients for extubation.  
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3.5 Postoperative patients 
It has been shown that NPPV in post-lung-resection patients with acute respiratory failure 
results in significantly less need for intubation, shorter ICU stay, and lower mortality rate 
than conventionally treated controls (Auriant et al. 2001) . The use of NPPV in selected 
postoperative patients (especially COPD patients) could maintain improved gas exchange 
and avoid reintubation and its complications. 
3.6 Do-not-intubate patients 
In the studies of patients in whom endotracheal intubation was contraindicated or 
postponed, COPD subgroup were supported with NPPV and weaned more successfully 
than the pneumonia or cancer subgroup of patients (Benhamou et al. 1992; Meduri et al. 
1994). Thus, NPPV is indicated in do-not-intubate patients with acutely reversible processes 
that are known to respond well, including COPD exacerbations. However, if NPPV is to be 
used in a do-not-intubate patient, the patient and/or the family should be informed that 
NPPV is being used as a form of life support that may be uncomfortable and can be 
removed at any time (Hill 2004).  
3.7 Overlap syndrome 
The term ‘’overlap syndrome’’ was introduced by Flenly to describe the association of 
obstructive sleep apnea syndrome (OSAS) and COPD (Flenley 1985). Even by chance alone, 
a patient with one of the disorders has a greater than 10% probability of also having the 
other disorder. Thus, when seeing a patient with either OSAS or COPD, it is reasonable to 
screen for the lower and longer nocturnal oxyhemoglobin desaturations, which produces 
more severe pulmonary hemodynamic complications (Chaouat et al. 1995; Bednarek et al. 
2005). Concomitant COPD in patients with severe OSAS so called critical care syndrome is 
frequently associated with diurnal hypercapnia and acute ventilatory failure (Fletcher et al. 
1991). There is an increase in the morbidity and mortality and risk of developing pulmonary 
hypertension and hypercapnic respiratory failure in patients with overlap syndrome than 
patients with OSAS alone and patients with usual COPD (Chaouat et al. 1995; Chaouat et al. 
1999). NPPV with or without supplemental oxygen is now the treatment of choice for the 
patients with overlap syndrome (Mayos et al. 2001).  
Improvement in daytime hypercapnia and gas exchange has been reported in overlap 
syndrome with continuous positive airway pressure (CPAP) treatment (Owens & Malhotra. 
2010). Mild bronchodilatory effect due to amelioration of chronic irritation and 
responsiveness of the upper airway and reduction of the chronic airway has also been 
suggested as the possible mechanisms for the benefits of CPAP. Bilevel positive airway 
pressure (BPAP) may be preferred if the patient experiences difficulty in exhaling against a 
fixed pressure or has persistent intermittent hypoxemia despite adequate airflow (Kushida 
et al. 2006). Supplemental oxygen can be added to NPPV to eliminate persistent intermittent 
nocturnal hypoxemia (Kakkar & Berry 2007). In a cohort of overlap syndrome patients, 
CPAP added to long term oxygen treatment as compared to long term oxygen treatment 
resulted in a survival benefit with 5 years-survival rates of 71% and 26%, respectively 
(Machado et al. 2010). In another study including COPD and overlap syndrome patients, 
CPAP therapy eliminated the additional risk of mortality due to OSA in overlap syndrome 
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patients as compared to COPD- only patients (Marin et al. 2010) . One RCT and another 
study using a historical cohort showed reduction of mortality in overlap syndrome with 
NPPV (McEvoy et al. 2009; Windisch et al. 2009). In the study by Windisch et al., intensive 
pressure settings (average inspiratory pressure 28 cm H2O, average expiratory pressure 5 
cm H2O and a high respiratory rate of about 21 breaths/min) were used with inhospital 
acclimatization and improvement in spirometry and arterial blood gas were reported 
(Windisch et al. 2009) . Finally, BPAP may be more comfortable and effective than CPAP in 
lowering CO2 and increasing tidal volume for patients with overlap syndrome, COPD 
component of which is much more related to moderate to severe hypercapnia and more 
prominent than the OSAS component. 
3.8 Severe stable COPD/Chronic respiratory failure in patients with COPD 
Despite the reported benefits of NPPV application in COPD patients with ARF, the role of 
NPPV in chronic respiratory failure (CRF) remains controversial. COPD patients with both 
increased hypercapnia and sleep-disordered breathing may be the ones, who are most likely 
to benefit from NPPV (Hill 2004). However the evidence to support the use of NPPV in CRF 
in the setting of severe stable COPD has been less consistent. COPD treatment guidelines 
does not recommend NPPV treatment routinely in end stage stable hypercapnic COPD in 
addition to conventional treatment (Global Initiative for Chronic Obstructive Lung Disease 
[GOLD] 2010).  
Once hypercapnia develops, 2-year mortality is approximately 30-40% (Foucher et al. 1998). 
The reported studies show some physiological benefits for the use of NPPV in stable COPD, 
but clear survival benefit has not yet been demonstrated (Leger et al. 1994; Jones et al. 1998; 
Tuggey, Plant, & Elliott 2003). All of these and most other studies used a moderately 
aggressive ventilation to treat stable hypercapnic COPD patients and so an impressive 
reduction in hypercapnia was not achieved. In contrast, more aggressive form of ventilation 
with mean IPAP of up to 30 cmH20 or even higher was used in recent studies by Windish et 
al. and a remarkable reduction of PC02 was achieved (Windisch et al. 2002; Windisch et al. 
2005; Windisch et al. 2006). Another RCT also has shown an improvement in survival with 
the application of nocturnal NPPV in end stage chronic hypercapnic COPD. The authors 
reported that the use of higher IPAP levels sufficient to be cardioprotective (but not to 
awake central respiratory drive) may result in greater treatment benefits (McEvoy et al. 
2009). High intensity NPPV therefore offers a new and promising therapeutic option in the 
treatment of patients with CRF. High intensity NPPV is better tolerated in patients with 
severe chronic hypecapnic COPD and has been shown to be superior to the conventional 
and widely used form of low intensity NPPV in controlling nocturnal hypoventilation 
(Dreher et al. 2010). Nevertheless, higher leak volume, side effects and impairments in sleep 
quality are the main disadvantages of this modality.  
NPPV might rest the chronically fatigued muscles and increase the muscle strength during 
daytime, could improve sleep time and efficiency, and sleep disordered breathing with 
episodes of hypoventilation. NPPV use in a select proportion of patients with severe stable 
COPD can improve gas exchange, exercise tolerance, dyspnea, work of breathing, frequency of 
hospitalisation, health-related quality of life and functional status (Kolodziej et al. 2007). 
Inconsistency in the effectiveness of all assessed outcomes may be due to the variability in 
degree of lung hyperinflation and NPPV levels and duration of use. As yet, no study has 
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provided convincing evidence that survival in COPD is prolonged by NPPV. Further work is 
also required to evaluate the effect of NPPV on reducing frequency and severity of COPD 
exacerbation. The general consensus, however, is that there is insufficient evidence to 
recommend NPPV for routine use in stable hypercapnic COPD (Kolodziej et al. 2007; Wijkstra 
et al. 2003). Despite the insufficient evidence, the ACCP consensus group opined that a trial of 
NPPV was justified with a symptomatic but stable and optimally treated patient who has 
daytime PaCO2 > 55 mm Hg, if OSA had been excluded. For PaCO2 between 50 and 54 mm 
Hg, , the ACCP consensus group suggested that there should be evidence of worsening 
hypoventilation during sleep, as suggested by a sustained (> 5 min) desaturation during use of 
the usual oxygen supplementation. In addition, the need for repeated hospitalizations was 
deemed a justification for a trial of NPPV (ACCP consensus conference 1999).  
The other limitation of NPPV use in patients with stable hypercapnic COPD is poor 
compliance to NPPV in this group of patients. Criner et al., found that only 50% of COPD 
patients were still using NPPV after 6 months, compared to 80% for neuromuscular patients 
(Criner et al. 1999). Reasons for poor adherence are unclear, but probably include the 
advanced age of COPD patients, frequent occurrence of co morbidities and cognitive 
defects, lack of motivation and appropriate/inefficient setting of NPPV. Close follow-up is 
probably helpful to optimize compliance rates.  
3.9 Sleep related hypoventilation/Hypoxemia due to COPD 
The latest edition of The International Classification of Sleep Disorders: Diagnostic and 
Coding Manual (ICSD-2) subsumes a broad range of disorders under the heading ‘’Sleep 
Related Hypoventilation/hypoxemic Syndromes.’’ (American Academy of Sleep Medicine. 
2005). Some are quite common, such as COPD with worsening gas exchange during sleep; 
while some are exceedingly rare, such as congenital central hypoventilation syndrome. The 
ICSD-2 manual recommended the use of NPPV in addition to optimal treatment of the 
underlying disorder in selected subgroups of the patients (Casey, Cantillo, & Brown 2007).  
In normal subjects, minute ventilation changes little, whereas minute ventilation in COPD 
patients falls approximately 16% from wakefulness to non REM sleep and almost 32% 
during REM sleep, compared to wakefulness, largely as a result of decreased tidal volumes. 
The greater drop in minute ventilation in subjects with COPD may reflect increased 
dependence on accessory muscles that become hypotonic during sleep, particularly in REM 
sleep leading to Sleep Related Hypoventilation/hypoxemic Syndrome due to COPD. 
NPPV devices are used during sleep to treat patients with Sleep Related Hypoventilation/ 
hypoxemic syndromes. Compelling evidence exists to support the use of NPPV during sleep 
in the management of selected Sleep Related Hypoventilation/ hypoxemic syndromes. NPPV 
has been used in Sleep Related Hypoventilation/ hypoxemic due to central respiratory control 
disturbances, restrictive thoracic cage disorders, neuromuscular diseases and the obesity 
hypoventilation syndrome. A select subgroup of COPD patients also appears to have 
improved sleep after treatment with NPPV but specific characteristics that describe this 
subgroup well remain to be elucidated. It is unclear whether exclusively nocturnal hypoxemia 
in these patients will be deleterious and therefore whether isolated sleep-related hypoxemia 
should be treated. COPD patients with clear evidence of hypoventilation while awake as 
evidenced by daytime hypercapnia are a reasonable starting target group. Those COPD 
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patients who also show continued sleep disruption or worsening hypercapnia and nocturnal 
hypoventilation despite oxygen therapy should be further investigated probably with 
polysomnography to rule out other sleep related breathing disorders. Finally we need to 
define optimal NPPV and interface design and settings in hopes of improving compliance of 
long-term therapy for all types of appropriate patients, who are likely to benefit from NPPV. 
3.10 Adjunct to exercise training in pulmonary rehabilitation programs 
Another potential application of NPPV in patients with severe stable COPD is to enhance 
exercise training during rehabilitation. It has been shown that when delivered during cycle 
ergometry, CPAP, pressure-support ventilation, and proportional-assist ventilation all 
reduce inspiratory effort and dyspnea in hypercapnic COPD patients (Petrof, Calderini, & 
Gottfried 1990; Bianchi et al. 1998). Recent studies in patients with severe COPD in a 6-week 
exercise training program has reported that, NPPV alone was more effective than 
supplemental oxygen alone as adjunct to physical exercise in improving submaximal 
exercise tolerance and health related quality of life (HRQOL) (Borghi-Silva et al. 2010). These 
studies demonstrated that NPPV can be used to increase or prolong the intensity of exercise 
training sessions in patients with severe COPD. 
4. Where to administer NPPV? 
Any patient on NPPV is classified as receiving Critical Care Level 2 care, defined as 
‘’Patients requiring more detailed observation or intervention including support for a single 
failed organ system’’. This suggest NPPV should be administered in an intensive care unit 
(ICU) or high dependency unit (HDU) setting, but it has been widely recognised that NPPV 
can be successfully used outside the ICU and HDU with dedicated NPPV team able to 
provide 24/7 care. This is however only feasible in large units with many trained staff 
(Manuel, Russell, & Jones. 2010). NPPV is more frequently used outside the ICU, in HDU, 
respiratory wards and emergency departments (EDs) (Brochard, Mancebo, & Elliott 2002; 
Hill 2004). It has been suggested that each hospital should have a specific designed area 
with experienced staff, where patients requiring NPPV can be transferred with the 
minimum delay (British Thoracic Society Standards of Care Committee  2002).  
5. Selection of optimal ventilator and mode of NPPV 
NPPV is broadly classified into volume preset and pressure preset devices, early studies of 
long-term domiciliary NPPV mainly concern patients on volume preset ventilators, whereas 
in the last 5-10 years pressure preset machines, particularly bilevel pressure support 
equipment has become more prominent.  
Volume preset machines gives the adjusted tidal volume regardless of mechanics of 
respiratory system (i.e. compliance, resistance and active inspiration) and if there is a leak 
from mask or mouth, patient cannot deliver the adjusted tidal volume. 
On the contrary pressure preset machines gives the adjusted pressure according to respiratory 
system mechanics by changing the flow and compensates the mask leaks. However pressure 
preset machines may not to be sufficient in patients who need high inspiratory pressure. 
Pressure support ventilators on a first line basis, especially with pressure support mode, is 
easier to adjust and to synchronise with the patient. CPAP and BPAP are the pressure support 
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ventilators. CPAP as the name implies, requires the airway pressure not to change between 
inspiration and expiration. However BPAP therapy was originally conceived with the idea of 
varying the administered pressure between the inspiratory and expiratory cycles. BPAP is the 
commonly used pressure preset method. BPAP devices deliver separately adjustable 
inspiratory positive airway pressure (IPAP) and expiratory positive airway pressure (EPAP). 
The IPAP and EPAP levels are adjusted to maintain upper airway patency, and the pressure 
support (PS=IPAP-EPAP), which augments ventilation.  
Three modes of NPPV were also defined according to principles of cycling of inspiration. 
NPPV devices can be used in the 1) spontaneous mode (the patient cycles the device from 
EPAP to IPAP), 2) the spontaneous timed (ST)/assisted-controlled (AC) mode (a backup 
rate is available to deliver IPAP for the set inspiratory time if the patient does not trigger an 
IPAP/EPAP cycle within a set time window otherwise patient the device from EPAP to 
IPAP), 3) the timed (T) /pressure controlled (PC) mode (patient cannot trigger and cycle the 
inspiration- inspiratory time and respiratory rate are fixed).  
Volume assured pressure support / volume target BPAP (VT-BPAP) which is a hybrid 
mode of volume preset and pressure support ventilation was available by the end of the 
1990s. Release of dual portable ventilators providing either pressure support ventilation or 
volume preset ventilation opened the way for new potent turbine pressure support 
ventilators able to deliver real volume ventilation with the average volume assured pressure 
support ventilation mode which represents a flexible way for managing the most difficult 
patients (Storre et al. 2006). Patient delivers the target tidal volume by the support of 
adjusted pressure support range. VT-BPAP has been developed in which the IPAP-EPAP 
difference is automatically adjusted to deliver a target tidal volume (Storre et al. 2006; 
Ambrogio et al. 2009; Janssens, Metzger, & Sforza 2009; Jaye et al. 2009) 
Proportional Assist Ventilation is another mode still under investigation. It provides a level 
of ventilatory assistance which is proportional to the patient’s respiratory effort throughout 
the respiratory cycle. Some studies reported better comfort and tolerance with proportional 
assist ventilation but found no differences in rates of mortality or intubation (Fernandez-
Vivas et al. 2003; Gay, Hess, & Hill 2001). Guidelines make no recommendation about the 
use of proportional assist ventilation versus pressure support ventilation in patients who are 
receiving NPPV for ARF, due to lack of sufficient evidence.  
6. Selection of interface 
Interfaces connect the patient’s airway to the NPPV tubing. The main six interfaces for 
NPPV are nasal mask, full face or oronasal mask, total face mask, helmet mask, nasal pillow 
or plugs and mouthpieces. Usually made of silicone, masks need to be carefully fitted to the 
individual to obtain optimum results. Variations include the bubble-type mask, and gel 
masks. Mask fit can be enhanced using mask cushions and seal/support rings which are 
supplied with the mask.  
Nasal mask: Nasal mask covers nose and does not cover mouth so allows speaking, drinking 
and cough also reduces the risk of vomiting and asphyxia. Disadvantages of nasal masks are 
air leaks if mouth opens, possible nasal skin damage and the need for patent nasal passages.  
Oronasal /Full face mask: Oronasal mask cover the nose and mouth and can prove valuable 
in patients with nasal airway blockage or acute confusional state. Oronasal mask is 
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recommended rather than nasal mask in patients who have ARF. Although there was no 
difference in endotracheal intubation or mortality rates, the oronasal mask was better 
tolerated (Keenan et al. 2011). The use of an oronasal mask seem a logical solution to 
maximize the NPPV efficacy, presumably due to lower leakage with oronasal mask 
compared to nasal mask in dyspneic patients who are mostly mouth-breathers (Carrey, 
Gottfried, & Levy 1990). However during long-term use the face mask can be poorly 
tolerated, thus causing a premature NPPV interruption (Carlucci et al. 2001).  
Total face mask: Total face mask covers mouth, nose and eyes. Advantages of this type of 
masks are minor air leaks, little cooperation required and easy fitting application. Risks of 
asphyxia, claustrophobia, speaking difficulty are the main disadvantages.  
Helmet: Helmet mask covers whole head and all or part of the neck without a contact with 
face. Advantages of this type of masks are minor air leaks, little cooperation required and 
absence of nasal or facial skin damage. The risk of vomiting, worsening of C02 clearance due 
to rebreathing, asynchrony with pressure support ventilation and discomfort of axillae are 
the disadvantages of the helmet.  
Nasal pillow or plugs: These masks are inserted into the nostrils. This type of the mask may 
be suitable for claustrophobic patients with chronic stable COPD who do not need high 
pressures. Nasal irritation is the main disadvantage. 
Mouthpieces: They are placed between lips and held in place by lip seal. Mouthpieces can 
be applied with other interfaces. The risk of vomiting and salivation, possible air leaks, 
gastric distension and speaking difficulty are the disadvantages of the mouthpieces. 
Mouthpiece ventilation is mainly used in patients with neuromuscular disease.  
7. Application, setting and adjustments of NPPV 
The first hours of NPPV are associated with an increased workload for health care personnel 
that requires a specific management protocol, including monitoring mask ventilation and 
monitoring the patient (Nava and Hill 2009). Recommended application, setting and 
adjustments of NPPV in the ICU, HDU, respiratory wards and emergency departments 
(EDs) are summarised as in the following:   
1. Explain technique to patient (if competent). 
2. Choose correct interfaces and size. 
3. Set pressure starting from low levels (minimum starting IPAP and EPAP should be 8 
cm H20 and 4 cm H20, respectively). 
4. Place mask gently over face, holding it in place and start ventilation. 
5. When patient is tolerant, tighten straps just enough to avoid major leaks, but not keep it 
too tight. 
6. Set Fi02 on ventilator or add low-flow oxygen into the circuit, aiming for S02>90%. 
7. Set alarms-low pressure alarm should be above PEEP level. 
8. Be mindful of and try to optimise patient’s comfort. 
9. Reset pressures (pressure support increased to obtain inspired tidal volume 6mL/kg or 
higher, achieving a respiratory rate <25 breaths/min, PaC02 <45 mmHg and also raise 
EPAP to obtain S02 of 90% or higher). The recommended maximum IPAP should be 30 
cm H20 for patients ≥ 12 years. The recommended minimum and maximum levels of PS 
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are 4 cm H20 and 20 cm H20, respectively. PS should be increased in order to optimize 
CO2 removal and control of auto-positive end expiratory pressure (PEEP), according to 
the patient’s tolerance. A backup rate (ST mode) should be used in all patients with low 
respiratory rate, in patients who unreliably trigger IPAP/EPAP cycle due to muscle 
weakness and in patients who do not achieve adequate ventilation or respiratory 
muscle rest with the maximum tolerated PS in the spontaneous mode. The inspiratory 
duration should be as short as possible. 
10. Protect site of skin pressure from the interface. 
11. Consider use of mild sedation if the patient is agitated. 
12. Monitor comfort, respiratory rate, oxygen saturation and dyspnea every 30 minute for 
6-12 hours and then hourly. 
13. Measure arterial blood gases at baseline and within 1 hour from the start.  
14. Humidification is advised for longer application.  
Predictors of NPPV failure are no improvement or a fall in pH and PC02, no change or a rise 
in breathing frequency after 1-2 hours and lack of cooperation. Delays in intubation of these 
patients run the risk of unanticipated respiratory or cardiac arrest with attended morbidity 
and mortality. NPPV failure occurs more frequently in the first hours of ventilation, and was 
reported to be predicted by the following clinical factors: severe acidosis, high severity 
score, severe impairment of consciousness, presence of co-morbidities and lack of 
improvement of arterial blood gases after 1-2 hours of initial ventilation (Ambrosino et al. 
1995; Elliott 2002; Nava & Ceriana 2004) 
8. Complications of NPPV 
Complications of NPPV therapy are minor and preventable. Major complications of NPPV 
such as pneumothorax and pneumocephalus are so rare (Grunstein 2005). The most 
common complications effecting almost half of the patients who are administered NPPV are 
due to mask leak and/or mask pressure injury (Pepin et al. 1999; Hoffstein et al. 1992; 
Abisheganaden et al. 1998; Lojander, Brander, & Ammala 1999; Sanders, Gruendl, & Rogers 
1986). The main complications of NPPV therapy are listed in Table 2. 
 
Due to Mask Due to Device 
Facial and nasal pressure injury/ 
ulcerations / pain 
Rhinitis, Rhinorrhea 
Mask allergy Sinusitis 
Conjunctivitis Tinnitus 
Dermatitis Otitis /ear pain 
Claustrophobia Epistaxis 
General Gastric distension 
Anxiety Dry mucous membranes and thick secretions 
Insomnia Aspiration of gastric contents 
Chest pain Barotrauma (pneumothorax, pneumocephalus) 
Headache Central Sleep Apnea 
Periodic Legs Movement 
Syndrome 
Hypotension related to positive intrathoracic 
pressure 
Table 2. Complications of NPPV Therapy 
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For COPD exacerbations NPPV should now be considered as a standard of care in properly 
selected patients, used in preference to invasive mechanical ventilation. Available evidence 
and experience have indicated that NPPV has an important role in managing COPD 
exacerbations, markedly by reducing the need for intubation and improving outcomes, 
including lowering complication and mortality rates, as well as shortening the hospital stay. 
NPPV can also be used in certain other situations in COPD patients: in respiratory failure 
precipitated by a superimposed pneumonia, in postoperative respiratory failure, in 
intubated patients to facilitate extubation with the aim of reducing the complications of 
prolonged intubation, in patients with postextubation failure to avoid reintubation, and in 
do-not-intubate patients; although the evidence to support these applications is not as 
strong as for NPPV in typical COPD exacerbations. For patients with severe stable COPD, 
currently available evidence suggests that NPPV can improve daytime and nocturnal gas 
exchange, prolong sleep duration, improve quality-of-life scores, and possibly reduce the 
need for hospitalization. However, the findings among studies have not been consistent on 
these benefits, partly related to numerous methodological shortcomings in most studies 
performed to date. Despite the weakness of the evidence base, however, some of the 
consensus and guidelines agree that COPD patients with substantial daytime carbon 
dioxide retention and evidence of superimposed nocturnal hypoventilation are the ones 
most likely to benefit (ACCP consensus conference 1999). Achieving desired NPPV 
adherence by COPD patients will remain still a challenge. Identification of eligible patients, 
establishment of the appropriate settings and close monitoring of the patients with trained 
staff are the key points of success of NPPV therapy. Technological improvement of NPPV 
devices and masks besides new guidelines on the selection of patient, ventilation mode and 
interface may achieve better NPPV adherence in patients with COPD in the future.  
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